News

News Contact

Ken Slepicka
kslepicka@synthonicsinc.com 540-443-3645
2200 Kraft Dr., Suite 2225
Blacksburg, VA 24060

May 30, 2017

Synthonics Receives License to Conduct Industrial Hemp Research

Synthonics, Inc. announced receipt of a license from the Commonwealth of Virginia's Department of Agriculture and Consumer Services (VDACS) to possess industrial hemp, which will allow Synthonics to research industrial hemp in their laboratory in Blacksburg, VA. This research will be conducted as a component of a VDACS-approved industrial hemp research program managed by a Virginia public institution of higher education.

Dr. Tom Piccariello, President and Chief Science Officer of Synthonics, stated: "We are very pleased that VDACS has granted us a license that will enable us to conduct research with industrial hemp. Industrial hemp could become a staple crop for the state of Virginia for many products. Our focus will be in applying the proprietary extraction process we have developed for use with medical marijuana to industrial hemp. The environmentally friendly process produces a purer (95% or more cannabinoid content) and more consistent powder in less time and at less cost than traditional purification processes. We believe that a pure powder of Cannabidiolic Acid (CBDA) from hemp leaves could have significant medical value. Recent preclinical studies have shown the potential medicinal benefits of CBDA, especially as therapy for anticipatory nausea in cancer patients on chemotherapy. CBDA also has anti-inflammatory and analgesic activity."

Ken Slepicka, CEO of Synthonics stated "Our goal is not only to develop a purification process of the hemp plant, but also to apply our metal coordinated technology to the pure CBDA that is derived from the hemp plant to produce a metallo-CBDA compound that can be more readily absorbed into the bloodstream to provide a faster onset of action for people with nausea and chronic pain. We are very excited for this opportunity to help people with these conditions through this license."

March 23, 2017

Synthonics Completes Cannabis Purification Process and Plans the Development of Metal Coordinated Cannabis Compounds for FDA Approval

Synthonics announced today that they have completed the development of a cannabis purification process and plans the development of metal coordinated cannabis compounds for eventual FDA approval to treat anticipatory nausea, chronic pain, refractory seizures, and other neurological disorders.

"We are pleased to report that we have completed the development of a purification process that converts extracted cannabis resin, which on average contains only 65% cannabis, to over 98% pure cannabis powder using our scalable extraction process. We believe that this novel method will save cannabis cultivators at least 40% of the cost of goods sold and greatly streamline their production operations" said Ken Slepicka, CEO of Synthonics. "Additionally, this process will allow the production of medical infused products free of unwanted plant material and other potential contaminants. We are planning to partner with cannabis cultivators and/or marijuana infused product companies in the states that have legalized medical marijuana."

"This efficient and inexpensive process to produce pure cannabis compounds will further our development of cannabis-based pharmaceuticals and ultimately lead to seeking regulatory approval to treat anticipatory nausea and other medical conditions" said Dr. Tom Piccariello, President and Chief Science Officer of Synthonics. "We want to thank Cresco Labs in IL as well as Harvest Inc. in AZ, both medical cannabis companies, for their support during our purification process development" said Ken Slepicka.

February 2, 2017

Synthonics Awarded Patents in Europe, Canada and Australia

Synthonics announced today the allowance of European patent EPO 14105/13, Canadian patent 2627343 both titled Metal Coordinated Compositions (allowing a claim for a metallo-Triiodothyronine) and Australian patents 2013205471, Metal Coordinated Compositions (claims for 15 metallo-compounds), 2013205088 Frequency Modulated Drug Delivery (FMDD) and 2011326137 Bismuth Containing Compounds for Modulating Properties of Biologically Active Agents.

"We are encouraged that Europe, Canada and Australia along with the US are recoginizing the novelness of our metal coordination invention," said Synthonics CEO, Kenneth Slepicka.  "To have global reach with our patents increases the value of our patent portfolio and reduces the risks for a potential licensor to commercialize one of our a metallo-compounds worldwide."

January 30, 2017

Synthonics Awarded Metal Coordinated Compositions Patents

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced today the allowance of US patent applicatons 14/290.877 and 14/547,803. This allowance from the United States Patent Office (USPTO) increases Synthonic's composition of matter patents to over 50 metallo-drugs.

"These newly allowed patents continue to demonstrate the novelness of our metal coordinated technology and is proving to follow our patent strategy to continue to add additional metallo-drugs from the list of drugs from our original patent application " said Synthonics CEO, Kenneth Slepicka.  "Intellectual property is important to our business and to our company and we are pleased that the USPTO recognizes our unique invention by allowing these additional metallo-drugs in a relatively short period of time."

August 10, 2016

Synthonics appoints Dr. Dean Stern to its Scientific Advisory Board

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced that its Board of Directors has appointed prominent Chicago podiatrist Dr. Dean Stern to its Scientific Advisory Board, chaired by Dr. Scott Palmer.

Ken Slepicka, CEO of Synthonics stated: "We are very pleased that Dr. Stern has accepted our appointment to the Scientific Advisory board. He brings a wealth of knowledge to our topical Magnesium-Furosemide compound project to treat chronic plantar warts.

Dr. Dean Stern stated: "I am excited to be part of the Synthonics Team to help provide my 35+ years of experience to further develop their topical Magnesium-Furosemide compound to treat plantar warts. I have been very impressed with the level of clearance, reduction of pain and the return of skin lines in our initial observations." Dr. Stern went on to say: "I will also provide the necessary inputs to the ongoing Synthonics metallo-antibiotic program that may hopefully help manage bacterial infections of the bone. I have seen too many of my patients lose a limb due to current ineffective antibacterial agents."

About Dr. Dean Stern

1976-present: Associate Professor, Department of Orthopedic Surgery Rush Presbyterian-St. Luke's Medical Center Chicago, Illinois
1976-Present: Associate Scientist Section of Biomechanics, Department of Orthopedic Surgery Rush Presbyterian-St. Luke's Medical Center Chicago, Illinois
1985-Present: Head of Podiatry Surgery, Department of Orthopedic Surgery Rush University Medical Center Chicago, Illinois and Rush Oak Park Hospital, Oak Park, Illinois
2013-Present: Chairman Section of Podiatry Surgery Rush Oak Park Hospital
2014-Present: Head of Medical Records Committee Rush Oak Park Hospital
April 2014: Fellow of American Association of Extremity Nerve Surgeons

 

May 15, 2016

Synthonics to Present and Showcase at the 2016 BIO International Conference in San Francisco June 6-9, 2016

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced today that it has been selected by the National Institute of Health (NIH) to showcase its MCP Technology at the 2016 BIO International Conference June 6-9th in San Francisco, CA.

Ken Slepicka, CEO of Synthonics stated: "We are very pleased that the NIH has once again selected Synthonics to exhibit at a kiosk in their sponsored Innovation Zone at this year's BIO," Ken further stated: "We are also delighted that Synthonics was chosen to present its capabilities on June 8th. This collaboration with the NIH continues to provide Synthonics with unique exposure at BIO, the world's largest biotechnology gathering. This event will allow us to reach out to high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies."

"NIH strongly believes in supporting innovative life science technology development through the SBIR program. BIO is an ideal convention to highlight our companies. The early-stage SBIR companies showcased in this year's Innovation Zone highlight some of the most promising technologies in our portfolio that we hope will achieve commercial success and significantly advance and improve human health. In order to achieve this goal, these companies require critical partnerships and capital. I encourage attendees to meet with our companies and explore the featured exhibits and presentations," said Dr. Matthew Portnoy, NIH SBIR/STTR program coordinator.

May 12, 2016

Dr. Tom Piccariello, President and Chief Science Officer, to present at the Global Drug Bioavailability Enhancement Summit in Boston, MA on May 12, 2016

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that Dr. Tom Piccariello has been selected to present "Examining the Advances and Development in Metal Coordinated Pharmaceutical (MCP) Compounds for Bioavailability Enhancement" at the Global Drug Bioavailability Enhancement Summit on May 12, 2016 in Boston.

Dr. Tom Piccariello, President and Chief Science Officer stated: "We are very pleased that the Bioavailability Summit selection committee asked me to represent Synthonics at this summit. I am very much looking forward to participating in the summit and presenting our novel technology and the advancements we have made in improving bioavailability of drugs, as well as learning more about the many advances that have been made in drug bioavailability enhancement."

 

April 15, 2016

Synthonics Awarded Metal Coordinated Compositions Patent

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced today the issuance of Canadian Patent No. 2,627,343. This composition of matter patent covers the complexes created through the attachment of any of seven metal ions to the active pharmaceutical ingredient Liothyronine (T3).

"This patent is our first from Canada and continues to build upon Synthonics' approach to improving the performance and reducing the adverse effects of active pharmaceutical ingredients. Liothyronine has numerous side effects that very often preclude physicians from prescribing T3 containing products. Recent studies, however, have demonstrated that many patients with hypothyroidism do not respond adequately to Synthroid (T4), alone, and would benefit from an improved formulation of T3" said Synthonics CEO, Kenneth Slepicka.  "Intellectual property is important to our business and to our company.  We are pleased that the Canadian Intellectual Property Office has recognized our invention with patent 2,627,343 expiring in 2026, and have further validated our MCP platform with the addition of a metallo-T3 composition of matter patent."

 

February 11, 2016

Dr. Tom Piccariello, President and Chief Science Officer, to speak and participate in a panel discussion at the 11th Annual Neurotech Investing and Partnering Conference

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that Dr. Tom Piccariello has been selected to speak and participate in a panel discussion entitled "Parkinson's and other Movement Disorders" at the Neurotech Investing and Partnering Conference to be held this April in Boston. NeuroTechConf.com

Dr. Tom Piccariello, President and Chief Science Officer stated: "We are very pleased that the Neurotech selection committee asked me to represent Synthonics and to the National Institute of Neurological Disorders and Stroke for their recommendation. I am very much looking forward to participating in the Conference, learning about the many advances that have been made in the neurological sciences, and sharing some of the progress that Synthonics has made."

Now in its 11th year, the Neurotech Investing and Partnering Conference is a premier partnering and investing conference for the neurotechnology industry including pharmaceuticals, medical devices, software and diagnostics for the brain and nervous system.

 

September 1, 2015

Synthonics Named a Finalist in the Redefining Early Stage Investments (RESI) Challenge

Synthonics will participate in the Redefining Early Stage Investments (RESI) Innovation Challenge in Boston on September 16, 2015. Synthonics is one of 30 innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare information technology chosen to compete by Life Science Nation (LSN). Kenneth Slepicka and John Borling will attend the conference pursuant to a grant from the National Institute of Health.

Learn more about the challenge RESI Challenge

About the RESI Conference
The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, secure funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more. The RESI Partnering Forum allows fundraising executives to identify and book up to 16 meetings with life science investors who fit their company's technology sector and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.

 

July 27, 2015

National Institute of Allergy and Infectious Disease (NIAID), Division of Microbiology and Infectious Diseases (DMID), to test Synthonics' Metallo-Zanamivir compound

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has agreed to test Synthonics' metallo-zanamivir compound in a mouse model. The request to the DMID is entitled "Evaluation of low doses of (propantheline tetrabromoferrate)(zanamivir)2 compared to zanamivir in influenza A virus infected mice by two routes of administration (IP and IV)."

Dr. Tom Piccariello states, "This a very positive development for Synthonics since the flu virus has been mutating around current therapies and we have the opportunity to demonstrate, with the help of the DMID, that we can accomplish our goal of producing a more effective anti-influenza therapy than currently available."

May 25, 2015

Synthonics to Showcase at the 2015 BIO International Conference

Synthonics, Inc. announced today that it has been selected by the National Institute of Health (NIH) to showcase its MCP Technology at the 2015 BIO International Conference June 15-18th in Philadelphia, PA.

Ken Slepicka, CEO of Synthonics stated: "We are very pleased that the NIH has selected Synthonics to exhibit at a kiosk in their sponsored Innovation Zone at this year's BIO," Ken further stated: "This collaboration with the NIH will provide Synthonics with unique exposure at BIO, which is the world’s largest biotechnology gathering. This event will allow us to reach out to high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies."

"NIH is committed to supporting exceptional innovation through the SBIR program. The early-stage companies showcased in this year’s Innovation Zone highlight some of the most promising technologies and significant non-dilutive Investments that we hope will achieve commercial success and significantly advance human health. In order to move toward this goal, however, these companies require critical partnerships and capital. I encourage attendees to meet with our companies and explore featured exhibits and presentations," said Dr. Lenka Fedorkova, NIH SBIR/STTR program manager.

April 14, 2015

Recipharm makes strategic investment in Synthonics and partners in development of novel compounds

Recipharm today announces that it has made an equity investment in Synthonics Inc and purchased $2.0 million of preferred stock in the company. A further $2.0 million of preferred stock will be purchased upon Synthonics' achievement of certain milestones, which could be expected during 2016. In addition, Synthonics and Recipharm have entered into a Joint Development Agreement under which Synthonics gains access to Recipharm's expertise in drug development, marketing and manufacturing in exchange for a royalty payment on certain of Synthonics' compounds. Synthonics has developed a unique drug delivery technology for metal coordination of pharmaceutical APIs. In connection with its investment, Recipharm's Carl-Johan Spak has joined Synthonics' board of directors.

Ken Slepicka, CEO of Synthonics, said: "Synthonics is delighted to extend the partnership with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm's formulation and development teams and expect this agreement and financial support to help us further advance several of our current projects to commercialization."

Carl-Johan Spak, Executive Vice President, Technology and Development, commented: "This transaction expands our footprint within the US and builds upon our existing Joint Marketing Agreement with Synthonics. In addition, it gives us an opportunity to share in the upside of Synthonics' chemistry, which we believe offers an elegant and cost-effective means to create patentable drugs that address difficult absorption and delivery issues. We believe that this collaboration will enhance our ability to serve our customers with exciting drug delivery solutions."

For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO Recipharm, thomas.eldered@recipharm.com, + 46 8'6025201
Carl-Johan Spak, EVP Development & Technology, carl-johan.spak@recipharm.com, +46 8 6025 313
Ken Slepicka, CEO Synthonics, (708)-209-1907, kslepicka@synthonisinc.com

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

March 25, 2015

Synthonics to Present at the 2015 Annual Angel Capital Association (ACA) Summit on April 14-16th, San Diego, CA

Blacksburg, VA ' Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that it has been selected as a guest of the National Institute of Health (NIH) to speak at the 2015 Annual Angel Capital Association Summit on April 14-16th in San Diego, CA. Synthonics' VP of Business Development, John Tinkham, will provide a corporate overview and update on lead compounds MCP-311 (bizmuth-levodopa) and metallo-T3, as well as its plans to develop patented cannibinoids, specifically metallo-CBDA/THCA compounds, to treat anticipatory nausea for cancer patients as well as other medical conditions.

September 29, 2014

Synthonics to Present at the 7th Annual Livingston Securities Life Sciences Stakeholders Summit on October 1st at the Cira Center in Philadelphia, PA.

Blacksburg, VA ' September 29, 2014 ' Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that it has been selected to speak at the 7th Annual Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 at the Cira Center in Philadelphia, PA. Synthonics' Founder and Chief Science Officer, Dr. Thomas Piccariello, will provide a corporate overview and update on its lead compound MCP-311 (bi-levodopa) and its plans to develop patented cannibinoids, specifically metallo-CBDA compounds, to treat anticipatory nausea for cancer patients as well as other medical conditions.

About Synthonics

Synthonics is a specialty pharmaceutical company focused on the discovery, development and licensing of patent-protected drugs (metal coordinated pharmaceuticals or "MCPs") that incorporate our proprietary metal coordination chemistry. MCPs have a profound effect on a variety of pharmacokinetic parameters including improved absorption, reduced toxicity, more reliable dosing, modified release and targeted delivery.

About Livingston Securities

Livingston Securities (www.livingstonsecurities.com) was founded in 2009 as a boutique investment bank & broker/dealer focused on three goals:

Livingston Securities is dedicated to providing corporate finance and strategic advisory services to corporate clients and sales, trading and related services to institutional investors and high net worth individuals who focus on disruptive technologies and their impact on healthcare, energy, infrastructure and other leading sectors of the American and global economy. Livingston Securities' goal is to provide a unique perspective and expertise on investments in nanotechnology and in companies that are commercializing and/or impacted by scientific advances in the emerging field of nanotechnology.

July 25, 2014

Synthonics Awarded Metal Coordinated Compositions Patent 8,779,175

Blacksburg, VA – Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced today the issuance of U.S. Patent No. 8,779,175. This composition of matter patent covers metal coordinated complexes that lower the pH levels at which an active agent can be kept in solution. “We have discovered buffering ligands which we can attach to a metal/drug complex that lowers the pH of the solution to enable innovative therapeutic formulations.  For instance, vorinostat is an oral drug to treat cutaneous T-cell lymphoma, but often times cannot be administered intravenously to afflicted patients because of the high pH needed to formulate the product.  With our newly patented technology we can convert vorinostat into a solution utilizing a buffering ligand to administer the metallo-vorinostat complex as an i.v. formulation while maintaining an acceptable pH of the solution” states Kenneth J. Slepicka, CEO of Synthonics.

The patent is a continuation of Synthonics' first filing and is the fifth granted to Synthonics. It significantly expands the universe of compounds covered by Synthonics’ patent estate and moves the company toward its goal of patenting thousands of novel combinations of metals and known pharmaceutical agents.

Synthonics attaches pharmaceutically acceptable metals, such as zinc, bismuth or magnesium, to active pharmaceutical agents to improve that agent’s delivery and performance. The metal used and the method of attachment affect the change imparted to the agent, which often allows Synthonics to "dial in" the desired pharmacokinetic property.

 "Intellectual property is important to our business and to our company.  We are pleased that the USPTO has recognized our invention with patent 8,779,175 and have further validated our MCP platform with the addition of these new compositions of matter." said CEO, Kenneth Slepicka.

July 21, 2014

NIH awards Synthonics, Inc. $497,790 for the third installment of the Phase II grant for its development of Metal Coordinated Levodopa

Blacksburg, VA – Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today the approval of its Progress Report and Budget in the amount of $497,790 for the third installment of a Phase II grant originally approved in July of 2012 by the National Institutes of Health (NIH). “The approval of the Progress Report and Budget continues to demonstrate Synthonics’ ability to meet timelines, advance the development of MCP-311 (metal coordinated levodopa) and control costs in the second year of the grant. With the final installment of the NIH grant, we can optimize the formulation of MCP-311 and file an Investigational New Drug Application (IND) to perform human studies in the 1st Quarter of 2015. ” says Kenneth Slepicka, Chief Executive Officer at Synthonics.

Synthonics' goal is to develop an orally administered product that will help patients worldwide who suffer from Parkinson’s disease better manage their symptoms. Although Parkinson’s disease cannot be cured, it can often be managed using levodopa, which appears to be uniquely capable of facilitating motor control among Parkinson’s disease patients. It has proven very difficult, however, to optimize the delivery of orally administered levodopa with currently available products. Patients are often required to take doses several times a day. Even with such frequent dosing, advanced Parkinson’s patients frequently have too much or too little of the drug in their bloodstream, resulting in abnormal and involuntary muscle movements.

Synthonics' metal coordination chemistry offers a promising new approach to controlled drug delivery. Synthonics binds levodopa to bismuth via a coordinate covalent bond, allowing it to adhere to the lining of the patient's gut, similar to how Pepto Bismol adheres to the stomach wall. The levodopa gradually detaches from the complex and is absorbed into the bloodstream. Synthonics' complex extends the therapeutic levels of levodopa to 20 hours in animals while substantially reducing the initial burst of absorption associated with muscle motor complications. This means the drug has the potential to work eight times longer than the immediate release product on today’s market. Additionally, the reduction in pulsatilility is expected to reduce the risks associated with long-term levodopa use and allow patients to enjoy the benefits of levodopa therapy without the usual complications

May 7, 2014

Synthonics to be Featured on the "Parkinson's Radio Hour" to be broadcast on WBZT AM 1230 Saturday May 10th, 2014 at 11AM EDT

Blacksburg, VA ' Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that Dr. Thomas Piccariello will be featured on the May 10th 11AM EDT broadcast of the "Parkinson's Radio Hour" on WBZT AM 1230. Dr. Piccariello will discuss Synthonics' lead compound MCP-311 (Bismuth-Subdopate) to treat the symptoms of Parkinson's disease. MCP-311 is formulated with Synthonics' proprietary metal coordination technology that in pre-clinical studies provides a steady release of levodopa beyond 20 hours vs. 3-4 hours with the current therapies. Synthonics is in the process of filing an Investigational New Drug (IND) application to the FDA to perform Phase I human clinical trials with MCP-311 in late 2014.

Also on the May 10th airing is a very engaging'discussion with one of our Directors and Chairman of our Business Advisory Committee, Ret. General John Borling regarding his book "Tapping on Walls."

The Parkinson's Radio Hour is a weekly broadcast with a mission to bring hope along with'the latest information on finding a cure for Parkinson's disease and'improving the quality of life for patients in South Florida. The typical show format includes a 'medical expert, research news, a person who is living with PD, quality of life advice and an inspirational guest. Jeff Dowd is the show's host. The Parkinson's Radio Hour's founding sponsor is the South Palm Beach County Chapter of the National Parkinson Foundation. Past broadcasts, including the one featuring Dr. Piccariello, can be listened to here: http://www.wbzt.com/media/podcast-parkinsons-radio-hour-parkinsonsradiohour/

 

May 5, 2014

Synthonics to Present at the prestigious Gordon Conference "Metals in Medicine" on June 23rd at the Proctor Academy in Andover, New Hampshire

Blacksburg, VA ' Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today that they have been selected to speak at the prestigious Gordon Conference "Metals in Medicine" on Monday June 23rd at the Proctor Academy in Andover, New Hampshire. Synthonics' Founder and Chief Science Officer, Dr. Thomas Piccariello, will be presenting "Medicines with Metals: Application of Coordination Chemistry to Improve Pharmacokinetics." The Gordon Research Conference is a non-profit organization managed by and for the benefit of the scientific community. This prestigious conference will provide an international forum for the presentation and discussion of frontier research in medicinal inorganic chemistry, with an emphasis on new unpublished results. The 2014 program will have a particular focus on defining what the future of medicinal inorganic chemistry will be and has attracted an outstanding scientific line-up.

 

August 21, 2013

NIH awards Synthonics, Inc. $816,958 for the second installment of the Phase II grant for its development of Metal Coordinated Levodopa

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals, announced today the approval of its Progress Report and Budget in the amount of $816,958 for the second installment of a Phase II grant originally approved in July of 2012 by the National Health Institute's (NIH). "The approval of the Progress Report and Budget demonstrates Synthonics' ability to meet timelines, advance the development of MCP-311 (metal coordinated levodopa) and control costs in the first year of the grant" says Kenneth Slepicka, Chief Executive Officer at Synthonics.

Synthonics' goal is to develop an orally administered product that will help patients worldwide who suffer from Parkinson's disease better manage their symptoms. Although Parkinson's disease cannot be cured, it can often be managed using levodopa, which appears to be uniquely capable of facilitating motor control among Parkinson's disease patients. It has proven very difficult, however, to optimize the delivery of orally administered levodopa with currently available products. Patients are often required to take doses several times a day. Even with such frequent dosing, advanced Parkinson's patients frequently have too much or too little of the drug in their bloodstream, resulting in abnormal and involuntary muscle movements.

 

May 7, 2013

Recipharm and Synthonics Join Forces to Promote Novel Drug Delivery Technology

Recipharm Pharmaceutical Development AB and Synthonics, Inc. announce today the formation of a Joint Promotion Agreement.

The contract, the first of its kind to be entered into between the two companies, will provide Recipharm customers full access to Synthonics' metal coordination chemistry, improving the delivery and performance of their compounds. Recipharm, a Swedish corporation, provides services that assist pharmaceutical companies throughout Europe, the United States, Japan and further afield with the development and formulation of products. Synthonics, a U.S. corporation, has developed a proprietary metal coordination chemistry that can significantly improve a compound's delivery and absorption.

Recipharm Pharmaceutical Development's General Manager, Maria Lundberg, commented, "We are pleased to partner with Synthonics to expand the services and solutions that we can offer our clients. The application of Synthonics' chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products. Furthermore, our ability to offer such services through this novel partnership distinguishes us from other CDMOs."

Ken Slepicka, CEO of Synthonics, stated that "Synthonics is delighted to partner with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm's formulation and development teams and believe that our chemistry will fit well in their existing tool kit of solutions. We expect this agreement to help us reach new clients and to expand the use of our chemistry."

About Recipharm
Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1600 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones and dry powder inhalers, oral liquids and granulates. For more information visit'www.recipharm.com.

About Synthonics
Synthonics, Inc. is a specialty pharmaceutical company focused on the discovery, development and licensing of patent-protected drugs (metal coordinated pharmaceuticals or 'MCPs') that incorporate its proprietary metal coordination chemistry. MCPs have a profound effect on a variety of pharmacokinetic parameters including improved absorption, reduced toxicity, more reliable dosing, modified release and targeted delivery.

For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail t.jervis@defacto.com.

 

March 6, 2013

Synthonics Awarded Metal Coordinated Compositions Patent

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery and development of metal coordinated pharmaceuticals (MCP), announced today the issuance of U.S. Patent No. 8,389,726. This composition of matter patent covers the complexes created through the attachment of any of eight metal ions to any of 20 active pharmaceutical ingredients.

The patent is a continuation of Synthonics' first filing and is the fourth granted to Synthonics. It significantly expands the universe of compounds covered by Synthonics' patent estate and moves the company toward its goal of patenting thousands of novel combinations of metals and known pharmaceutical agents.

Synthonics attaches pharmaceutically acceptable metals, such as zinc, bismuth or magnesium, to active pharmaceutical agents to improve that agent's delivery and performance. The metal used and the method of attachment affect the change imparted to the agent, which often allows Synthonics to "dial in" the desired pharmacokinetic property.

"This patent describes Synthonics" approach to improving the performance and/or reducing the adverse effects of 20 active pharmaceutical ingredients that have been already approved by the FDA." said Synthonics CEO, Kenneth Slepicka. '"Intellectual property is important to our business and to our company.' We are pleased that the USPTO has recognized our invention with patent 8,389,726 and have further validated our MCP platform with the addition of these new compositions of matter."

 

November 26, 2012

Synthonics to Present at the Therapeutic Area Partnerships Meeting

Synthonics, Inc., a specialty pharmaceutical company focused on the discovery, development and licensing of drugs that incorporate a proprietary metal coordination chemistry, today announced that President and Chief Science Officer, Dr. Thomas Piccarriello, will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA. Dr. Piccariello will present an overview of the company's Metal Coordinated Pharmaceutical (MCP) technology and its use to control the release of furosemide. Windhover has named Synthonics' patented compound MCP-111 (magnesium-furosemide) a "Top 10 Project to Watch in Cardiovascular/Metabolic."

Dr. Piccariello will be presenting on Thursday, November 29 at 4:30 p.m. EST at the Westin Copley Place during the Cardiovascular/Metabolic Projects to Watch session. Therapeutic Area Partnerships is one of the industry's premier biopharmaceutical partnering events. More information can be found on the meeting's web site: www.tapartnerships.com.

 

July 19, 2012

NIH awards Synthonics, Inc. a $2 mil Phase 2 grant for
its development of Metal Coordinated Levodopa

Building on work funded in part by a Phase 1 grant from the NINDS and a subsequent grant from the Michael J. Fox Foundation, Synthonics, Inc. has been awarded a Phase 2 grant from the NINDS worth over $2 million to advance the development of MCP-311, its controlled release levodopa complex for patients suffering from Parkinson's disease. Synthonics will use the grant proceeds to fund the formulation refinement and preclinical studies associated with filing an investigational new drug (IND) application. Synthonics intends to file an IND application for MCP-311 and to license the compound to a pharmaceutical partner that will carry the product through the NDA process to commercialization.

Synthonics' goal is to develop an orally administered product that will help the 500,000 to 1,200,000 Americans that suffer from Parkinson's disease better manage their symptoms. Although Parkinson's disease cannot be cured, it can often be managed using levodopa, which appears to be uniquely capable of facilitating motor control among Parkinson's disease patients. It has proven very difficult, however, to control the release of orally administered levodopa products and patients using such products often must take them several times a day. Even with such frequent dosing, advanced Parkinson's patients often have too much or too little of the drug in their bloodstream, resulting in abnormal and involuntary muscle movements.

Synthonics' chemistry offers a promising new approach to controlled drug delivery. Synthonics binds levodopa to bismuth via a coordinated covalent bond, modifying the drug's pharmacokinetics, allowing it to attach to the lining of the patient's gut. The levodopa gradually detaches from the complex and enters the bloodstream at a more controlled rate. Synthonics' complex extends the therapeutic levels to 24 hours in animals while substantially reducing the initial burst of absorption associated with abnormal muscle movement. This means the drug has the potential to work eight times longer than the immediate release product on today's market. Additionally, the reduction in pulsatilility would reduce the risks associated with long-term levodopa use and allow patients to enjoy the benefits of levodopa therapy without the usual complications.

 

March 2, 2012

Synthonics, Inc. is a 2012 Finalist for the Virginia Healthcare Innovators Awards

Synthonics has been nominated as a Virginia Healthcare Innovator of the Year. Synthonics' Metal Coordinated Pharmaceuticals platform technology was recently nominated and selected as a finalist under the category Medical Product or Device for the Virginia Healthcare Innovator of the Year Award.

Synthonics' innovative approach uses metal coordination to address pharmaceutical issues with absorption, delivery, and toxicity. Using the ligand field properties associated with metals, Synthonics can simply and elegantly form a metal coordination complex to the pharmaceuticals. Such complexes have a profound effect on a variety of pharmacokinetic parameters including modified release and targeted delivery of the active pharmaceutical ingredients. Furthermore, the complex may provide a reduction of intersubject variability by enabling faster and fuller absorption. Synthonics is honored to be recognized for its unique approach to addressing a medication's impact on patient outcomes and the potential benefit this technology could have on a wide variety of pharmaceuticals.

 

December 21, 2011

Synthonics receives SBIR Matching Grants from CIT-CRCF

The Center for Innovative Technology (CIT) announced today that Synthonics was awarded a SBIR Matching Grant from the Commonwealth Research and Commercialization Fund (CRCF). The awards totaling $3.6 million were made to 22 organizations from academia, the research community, and industry in the Commonwealth for the purpose of funding targeted areas of research with commercial promise aligned with the Commonwealth Research and Technology Strategic Roadmap.

This CRCF grant will be used to further advance Synthonic's novel MCP (metal coordinated pharmaceutical) chemistry for its metallo-levodopa compound to treat Parkinson's Disease.

Synthonics, Inc.     2200 Kraft Drive, Suite 2225      Blacksburg, VA 24060     Phone (540) 443-3645